Neurocrine Biosciences Inc
XMUN:NB3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Neurocrine Biosciences Inc
XMUN:NB3
|
US |
|
M
|
MOBIX LABS, INC.
NASDAQ:MOBX
|
US |
|
H
|
Host Hotels & Resorts Inc
F:HMT
|
US |
|
L
|
Liveramp Holdings Inc
F:XIM
|
US |
|
C
|
CenterPoint Energy Inc
F:HOU
|
US |
|
F
|
Foot Locker Inc
F:WOO
|
US |
|
J
|
JAFCO Group Co Ltd
F:JAF
|
JP |
|
D
|
De La Rue PLC
DUS:DL1C
|
UK |
|
Evertec Inc
F:2EV
|
PR |
|
P
|
PDF Solutions Inc
F:PD9
|
US |
|
J
|
JB Hi-Fi Ltd
F:JB3
|
AU |
Wall St Price Targets
NB3 Price Targets Summary
Neurocrine Biosciences Inc
According to Wall Street analysts, the average 1-year price target for NB3 is 165.73 EUR with a low forecast of 125.66 EUR and a high forecast of 223.18 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NB3's stock price target?
Price Target
165.73
EUR
According to Wall Street analysts, the average 1-year price target for NB3 is 165.73 EUR with a low forecast of 125.66 EUR and a high forecast of 223.18 EUR.
What is the Revenue forecast for Neurocrine Biosciences Inc?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
30%
Over the last 13 years, the compound annual growth rate for Operating Income has been 53%. The projected CAGR for the next 8 years is 30%.
What is the Net Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
18%
Over the last 13 years, the compound annual growth rate for Net Income has been 42%. The projected CAGR for the next 8 years is 18%.
